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 Abstract 
Osteoporosis is a common age-related disease that increases the risk 
of fractures. Androgens are crucial for bone health in males. 
Although a substantial part of the effects of androgens on the 
skeleton is mediated via conversion of testosterone to estradiol, 
direct effects of androgens on the androgen receptor (AR) also 
contribute to male bone homeostasis. The aim of this thesis is to 
increase the knowledge about the significance of the AR for bone 
metabolism to potentially identify bone-specific AR signaling 
pathways.  
The thesis is based on studies using several different mouse 
models with altered AR signaling. In Paper I, we demonstrated that 
inactivation of the AR in immature osteoblast-lineage cells reduces 
trabecular but not cortical bone mass. Since antiandrogens are 
frequently used in the treatment of men with prostate cancer, we 
investigated the possible skeletal side effects of the recently 
approved antiandrogen drug enzalutamide (Paper II). Although this 
drug effectively reduced the weights of androgen-sensitive 
reproductive tissues, bone mass was reduced moderately and only in 
the axial skeleton.	 To determine the importance of the AR for pu-
bertal and adult bone metabolism, avoiding confounding 
developmental effects, we inactivated the AR in pre-pubertal as well 
as in young adult male mice (Paper III). We demonstrated that 
adult AR expression is crucial for trabecular and cortical bone mass 
maintenance while pubertal AR expression is crucial for normal fat 
mass homeostasis in adult male mice. The AR activity is regulated 
by post-translational modifications, including AR SUMOylation. In 
Paper IV, we demonstrated that AR SUMOylation regulates bone 
mass but not the weights of androgen-responsive reproductive 
tissues, suggesting that therapies targeting AR SUMOylation might 
result in bone-specific anabolic effects with minimal adverse effects 
in other tissues.  
The findings in this thesis contribute with important knowledge 
for the development of new treatment options for men with 
osteoporosis and safer endocrine treatments, with minimal skeletal 
side effects, for men with prostate cancer. 
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 Sammanfattning på svenska 
Osteoporos, benskörhet, är en åldersrelaterad folksjukdom som ökar 
risken för frakturer. Mäns skelett regleras av kroppens androgener 
där en väsentlig del av effekterna på skelettet sker via omvandling 
av testosteron till östradiol. Skelettet påverkas även av att androge-
ner aktiverar androgenreceptorer (AR). Syftet med denna avhand-
ling har varit att öka kunskapen kring ARs betydelse för 
benmetabolismen i relation till andra androgenkänsliga organ för att 
på sikt kunna identifiera skelettspecifika signaleringsvägar via AR. 
Avhandlingen baseras på experiment med musmodeller som på 
olika sätt har förändrad möjlighet att signalera via AR. I delarbete I 
studerade vi skelettet hos möss vars alla celler som härstammar från 
omogna osteoblastceller saknar uttryck av AR. Resultaten visade att 
signalering via AR i osteoblaster är av betydelse för det trabekulära 
men inte för det kortikala benet. Eftersom män som drabbats av 
prostatacancer ofta behandlas med antiandrogener. undersökte vi i 
delarbete II hur ett nyligen godkänt antiandrogenläkemedel, enza-
lutamid, påverkar skelettet hos möss. Studien visade att behandling 
medförde en minskning av benmassan i det axiala men inte i det 
appendikulära skelettet. Genom en inducerbar knockoutmodell stu-
derade vi därefter i delarbete III hur det vuxna djurets skelett på-
verkas då AR inaktiverats strax innan respektive direkt efter 
puberteten. Resultaten klargjorde att en bibehållen funktionell AR är 
nödvändig för att upprätthålla benmassan hos vuxna hanmöss. Akti-
viteten av AR regleras av post-translationella modifieringar såsom 
SUMOylering. I delarbete IV undersökte vi betydelsen av 
SUMOylering av AR. Resultaten visade att möjlighet till SUMOyle-
ring av AR är nödvändig för reglering av benmassan medan andra 
androgenkänsliga reproduktiva organ inte påverkades. Läkemedel 
som riktar sig mot SUMOyleringsförmågan av AR kan därmed tro-
ligtvis resultera i benspecifika anabola effekter med minimala bi-
verkningar i andra organ.  
Resultaten från denna avhandling tillför värdefull kunskap till ut-
vecklingen av nya behandlingsalternativ för patienter med osteopo-
ros samt bidrar med information kring säkrare behandlingar, med 
minimala skelettbiverkningar, för män med prostatacancer. 
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1. Introduction 
Osteoporosis is a common age-related disease that increases the risk of 
bone fractures, not only in women but also in men. Androgens, such as 
testosterone (T), have been identified as key determinants for male bone 
health. However, treatment with androgens may lead to side effects such 
as increased risk of cardiovascular diseases and increased risk of prostate 
cancer due to a stimulation of the prostate. Therefore, increased 
knowledge about the signaling mechanisms of androgens via the 
androgen receptor (AR) is needed for the development of new bone-
specific selective androgen receptor modulators (SARMs) with minimal 
systemic side effects. There is also a need for more knowledge about the 
possible skeletal side effects of newly developed drugs for prostate 
cancer.   
1.1 Skeletal physiology 
The skeleton is a vital organ for vertebrates and it is made of bone cells 
and extracellular mineralized matrix. The adult human skeleton is com-
posed of 206 bones and is usually categorized as the axial skeleton, in-
cluding the skull, rib cage and vertebral column, and the appendicular 
skeleton, including the upper and lower limbs, shoulders, and pelvis.  
 
The skeleton consists of two different types of bone, the cortical and 
trabecular (cancellous) bone. Cortical bone forms the compact outer shell 
of the bone, and contributes to 80% of the weight of the human 
skeleton(1,2). It supports the whole body, provides localization for muscle 
and nerve growth, protects pivotal organs, such as brain and heart, and 
stores and releases chemical elements, mainly calcium and phosphate. 
Trabecular bone is located within the bones and has higher bone surface 
area per volume than cortical bone, which is suitable for metabolic 
activity, e.g. exchange of calcium ions. Trabecular bone is typically 
found within the ends of the long bones and accounts for more than 70% 
of the interior of vertebrae(3,4).  
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The long bones have three 
distinct parts: epiphysis, 
metaphysis and diaphysis 
(Figure 1). The epiphysis is 
the wider section at each end 
of the long bone and it is 
composed of cortical bone on 
the outside and trabecular 
bone on the inside. The 
midsection shaft of the long 
bone is called diaphysis and is 
composed of cortical bone 
surrounding a central marrow 
cavity containing bone 
marrow and fat. The 
metaphysis, located between 
the epiphysis and diaphysis, 
contains the growth plate.  
1.2 Bone cells 
Osteoblasts are derived from mesenchymal stem cells (MSCs) and are 
responsible for the generation of new bone matrix. MSCs can be isolated 
from bone marrow and most connective tissues (5,6). MSCs are capable of 
differentiating into diverse cell lineages (adipocytes, chondrocytes, 
myoblasts, fibroblasts, and osteoblasts) in a process controlled by various 
cytokines, growth factors, and transcription factors (Figure 2). For 
instance, PPARγ is a key transcription factor for the differentiation of 
MCSs into adipocytes while Sox9 and MyoD are key transcription 
factors for the differentiation of MCSs into chondrocytes and myoblasts, 
respectively(7). The osteoblast differentiation occurs through a multi-step 
molecular pathway regulated by different transcription factors and 
signaling proteins including Wnts, Notch and bone morphogenetic 
proteins (BMPs)(8,9). Runx2 (also known as Cbfa1) is a transcription 
factor necessary for the progress of MSCs into osteoprogenitor cells 
whereas Osx1 (also known as Sp7) is required for the differentiation of 
pre-osteoblasts into mature osteoblasts. Mature osteoblasts express 
alkaline phosphatase (ALP) osteocalcin (OCN) and collagen 1α1 
(Col1α1). Mature osteoblasts can further differentiate into bone-lining 
Figure 1 Longitudinal µCT scan image of distal femur 
from an adult male mouse. Scanned by Jianyao Wu.  
epiphysis
(rich in trabecular bone)
diaphysis
(rich in cor!cal bone)
metaphysis
(includes growth plate)
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cells or mechano-sensing osteocytes, which are embedded in the matrix 
and express DMP1 and sclerostin(8,9).  
Figure 2 Osteoblast differentiation. Adapted from “Molecular mechanisms of mesenchymal stem cell 
differentiation towards osteoblasts” by Fakhry M et al, 2013, World Journal of Stem Cells, p136-
148. CC BY-NC 4.0. 
Osteoclasts are specialized bone resorbing multinuclear cells, derived 
from hematopoietic precursors and distributed on the bone surface(10,11). 
Initially, bone marrow macrophages differentiate into tartrate-resistant 
acid phosphatase (TRAP)-positive preosteoclasts (Figure 3). The 
preosteoclasts fuse with each other to form multinucleated osteoclasts. 
Generation of osteoclasts require binding of two ligands: the macrophage 
colony-stimulating factor (M-CSF) to its receptor c-Fms and RANKL 
(the receptor activator of nuclear factor kappa B (NF-κB) ligand), also 
known as TNFSF11, to its receptor RANK(12,13). The RANKL-stimulated 
osteoclastogenesis is inhibited by the RANKL decoy receptor 
osteoprotegerin (OPG) expressed by osteoblast lineage cells. 
Furthermore, cytokines such as IL-1 and TNF-α also regulate 
osteoclastogenesis. The master transcription factor for osteoclast 
differentiation and function is NFATc1 (nuclear factor of activated T-
cells, cytoplasmic 1) whereas the degradation of the organic component 
of bone matrix is accomplished by different enzymes including the 
lysosomal proteolytic enzyme cathepsin K. 
 
 
 
 
 
 
Mesenchymal
    stem cell
Osteoprogenitor Pre-osteoblast Mature osteoblast
Osteocyte
Bone lining cell
Osx1 Col1a1
DMP
1
Runx2
Myoblast
MyoD
PPARγ
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Figure 3 Osteoclast differentiation. Adapted from “Osteoclast differentiation and activation” by 
Boyle WJ, Simonet WS, and Lacey DL, 2003, Nature, p337-342. Reprint with permission from the 
publisher. 
1.3 Bone modeling and remodeling 
 
There are two modes of bone formation in mammals – endochondral and 
intramembranous ossification, both involving transformation of 
mesenchymal tissue or cartilage into bone tissue(14). The main growth and 
development of the skeleton occurs until the end of sexual maturation(15). 
This period is referred to as modeling phase. During the modeling phase, 
the activities of the osteoblasts and osteoclasts are mainly uncoupled and 
the bone formation rate exceeds bone resorption leading to a net increase 
in bone mass. In addition to this accrual of bone mass, substantial 
changes in the gross morphology of the bone can be observed. The 
morphologic changes include longitudinal growth of the long bones, 
which is achieved by bone formation at the epiphyseal growth plates, and 
radial growth due to bone formation on the outer surface of the cortex 
(periosteal apposition) and resorption on the inner surface (endosteal 
resorption). The epiphyseal growth plates gradually close in humans at 
the end of puberty and longitudinal growth is thereby completed(16,17).  
 
The size of the bones differs between the genders(18,19). Men are on 
average 10% taller and have larger bone width than women. This 
observation is considered to be mainly due to the greater periosteal 
expansion during puberty and early adulthood in boys, whereas girls 
predominantly increase their cortical thickness by limiting endocortical 
expansion(20,21).  
 
   Fused polykaryon Ac!vated osteoclastPre-osteoclastHematopoie!c precusor
M-SCFM-SCF
RANKL
RANKL
OPG OPG
IL-1TNF
-α 
Cathepsin K
NFA
Tc1 NFA
Tc1
TNF-α IL-1
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osteoclasts osteoblasts bone lining cells
osteocytes
bone !ssues
Bone is an extremely dynamic organ. During lifetime, old bone tissue 
with micro-damages is continuously replaced by newly formed bone 
tissue so that it constantly adapts to mechanical load and strain(22). This 
process is called bone remodeling(23). Bone remodeling takes place in 
what Frost termed the basic multicellular unit (BMU), which comprises 
the osteoclasts, osteoblasts, and osteocytes within the bone-remodeling 
cavity (Figure 4). The remodeling cycle consists of four consecutive 
phases: activation, resorption, reversal, and formation(24). The remodeling 
begins with the migration of partially differentiated mononuclear 
preosteoclasts to the bone surface where they get activated and form 
large multinucleated osteoclasts. The osteoclasts bind to the bone surface 
with adhesive proteins, creating a closed microenvironment where acidic 
hydrogen ions and proteolytic enzymes are secreted to resorb bone tissue. 
After the completion of osteoclastic bone resorption, there is a reversal 
phase when mononuclear cells appear on the bone surface. These cells 
prepare the surface for new osteoblasts to begin bone formation and 
provide signals for osteoblast differentiation and migration. The 
formation phase follows with osteoblasts laying down bone until the 
resorbed bone is completely replaced by new. When this phase is 
complete, the surface is covered with flattened lining cells and a 
prolonged resting period begins until a new remodeling cycle is initiated. 
 
In humans, the rate of bone remodeling is 5-10% per year; hence most of 
the skeleton will be replaced within 10 years(25). During normal bone 
remodeling, the resorbed bone is completely replaced by new bone. This 
is secured through tight coupling of bone resorption to bone formation(26). 
Although the mechanisms underlying the coupling process still remain 
largely unknown, the process is modulated by a wide variety of hormones 
and locally generated cytokines secreted in response to mechanical 
stimulation and microdamage(26). 
Figure 4 Bone cells in remodeling process. Adapted from “Bone-tissue engineering: complex tunable 
structural and biological responses to injury, drug delivery, and cell-based therapies” by Alghazali 
KM et al, 2015, Drug Metabolism Reviews, p431-454. Reprint with permission from the publisher. 
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1.4 Osteoporosis 
Osteoporosis is a systemic metabolic bone disease which is characterized 
by low bone mass and deterioration of bone microstructure, leading to 
enhanced bone fragility and increased fracture risk. Osteoporosis-related 
fractures, especially hip fractures, constitute major health concerns 
worldwide in terms of both human suffering and financial cost. The 
lifetime risk at age 50 of having a fragility fracture is about 20% for men 
and 50% for women in Sweden(27). In 1994, the World Health 
Organization (WHO) established the criteria for osteoporosis diagnosis in 
women(28) and it is defined as an areal bone mineral density (aBMD) of 
either the hip or spine below -2.5  standard deviations (SD) of the mean 
in young adult women (T-score)(28). There is no absolute diagnostic 
criteria established for men, although the common practice is to use the 
same criteria as for women with a young male population as reference. 
 
In secondary osteoporosis, the bone loss is not due to aging or 
postmenopausal status but instead caused by other diseases including in-
flammatory or endocrine disorders, cancers, or medical therapies(29-31). 
Cancer-associated bone loss can result from the primary disease itself, 
either due to circulating bone resorbing substances or metastatic bone 
disease, or from the therapies administered to treat the primary 
condition(32). In the former case, generalized bone loss is caused by circu-
lating bone resorbing hormones or cytokines, such as parathyroid hor-
mone-related protein (PTHrP), RANKL, IL-6 or IL-3, produced by the 
tumor or local effects of the metastatic deposit(33-35). In the latter case, 
bone loss is due to therapies such as chemotherapeutics, corticosteroids, 
aromatase inhibitors or androgen deprivation therapy (ADT)(35). Estrogen 
deprivation therapy in women with breast cancer and ADT in men with 
prostate cancer accelerate bone turnover leading to a decrease in BMD 
and an increased fracture incidence(36).  
1.5 Male osteoporosis 
Osteoporosis is not as common in men as in women, but with the aging 
of the population, osteoporosis in men is becoming an increasingly im-
portant public health problem. Recent studies have demonstrated that in 
men, just like in women, trabecular bone loss begins in young adult life, 
whereas cortical bone loss begins after midlife(21,37). Hip fractures con-
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tribute to the greatest morbidity and mortality among all osteoporotic 
fractures, and the severe consequences of hip fractures are more pro-
nounced in men compared with women(27). However, the proportion of 
men with fractures treated with osteoporosis drugs is lower than the pro-
portion of women treated(38). Importantly, higher mortality after low-
trauma fracture has been demonstrated in men when compared with 
women(39). 
1.6 Fracture risk assessment 
Although low BMD is a major risk factor for osteoporotic fractures, 
several other important risk factors such as gender, age, previous 
osteoporotic fracture, family history of hip fractures, and systemic 
glucocorticoid treatment have been described(40,41). In addition, low body 
weight, smoking, high alcohol consumption, insufficient vitamin D 
intake, hypogonadism, early menopause in women, inactivity and risk 
factors for falling have been described to associate with increased risk of 
fractures. In order to take several identified risk factors into account for 
fracture risk assessment, the web-based fracture risk assessment tool 
FRAX® was introduced(42). It uses an algorithm to compute the 10-year 
probability of hip fracture and/or major osteoporotic fracture in 
individuals by integrating several important individual clinical risk 
factors for fracture, with or without the addition of femoral neck BMD. 
The risk is calculated in a population-specific manner, where the absolute 
fracture risk varies according to the selected country 
(https://www.sheffield.ac.uk/FRAX/). 
1.7 Androgens 
Sex steroids include androgens, such as T and dihydrotestosterone 
(DHT), and estrogens, such as 17β-estradiol (E2) and estrone (E1), and 
are predominately produced by the testes in men and ovaries in women. 
In addition to the gonadal sex steroids, the human adrenal cortex produc-
es substantial amounts of the sex steroid precursors dehydroepiandros-
terone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), which 
can be locally converted into androgens and estrogens in both males and 
females. In contrast to humans and higher primates, the adrenal gland of 
adult rodents (e.g. rats and mice) produce little or no DHEA(43), but their 
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adrenals produce substantial amounts of the androgen precursor andros-
tenedione(44). Androgens are crucial for the development of male repro-
ductive tissues such as the testis and prostate. In addition, they exert 
several other important effects on muscle mass, bone mass and fat distri-
bution. 
 
The production of T is regulated by the hypothalamic-pituitary-gonadal 
axis (45,46). Gonadotropin-releasing hormone (GnRH) from the hypothal-
amus stimulates pituitary release of luteinizing hormone (LH) that stimu-
lates the production of T in the Leydig cells in the testes. In peripheral 
tissues, T can be converted by 5α-reductase enzymes (Srd5α1 and 
Srd5α2) into the more potent androgen DHT (47,48). T can also be convert-
ed into E2 by the aromatase (CYP19A1) enzyme (Figure 5). In the hu-
man circulation, ~98% of the T is bound to albumin or sex hormone-
binding globulin  (SHBG) with only a small fraction being free (~2%)(49).  
1.8 Androgen receptor (AR)  
Androgens mediate their effects mainly through the AR that is a DNA-
binding transcription factor(50,51). The AR is found in many different types 
of cells in tissues such as testes, prostate, breast, uterus, muscles and 
skeleton(52-54). In the absence of androgens, the AR is localized to the 
cytoplasm. Upon addition of androgens, the AR is translocated to the 
nucleus where the liganded-AR transactivates downstream genes. 
The AR gene is located on chromosome Xq11–12 and is encoded by 
eight exons(55,56). It consists of four unique domains: the N-terminal 
transactivation domain (NTD), the DNA-binding domain (DBD), the 
hinge region (H), and the ligand binding domain (LBD)(57). The NTD is 
fully encoded by exon 1 and it contains the activation function-1 (AF-1), 
which is crucial for the AR’s transcriptional activities(58,59). The DBD 
encoded by exons 2 and 3, is critical for the specific binding of the AR to 
Figure 5 The androgen receptor (AR) and estrogen receptors (ER) α and β can be activated directly 
or indirectly by testosterone. 
Testosterone
DHT
Androgen Receptor
Estrogen Receptor α
Estrogen Receptor β
5α-reductase
Aromatase E2
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androgen responsive elements and the stabilization of DNA-receptor 
interactions(60,61). The 5ʹ region of exon 4 encodes the hinge region that 
contains the nuclear localization signal(62,63). The 3ʹ region of exon 4 and 
exons 5–8 encode the LBD that contains activation function-2 (AF-2), 
which is important for the ligand-dependent activation of the receptor 
(Figure 6)(64,65).  
 
Although activation of the AR is highly dependent on a ligand, ligand-
independent activation of the AR is also possible. Ligand-independent 
mechanisms of AR activation and altered AR transcriptional activity 
include AR activation by growth factors such as IGF-1 and EGF(66), the 
receptor tyrosine kinase–activated pathway (HER-2/neu signaling 
cascade; Src kinase)(67-69), and the AKT pathway(70). 
1.9 SUMOylation of the AR 
The AR activity is regulated by several different post-translational 
modifications (PTMs), including phosphorylation, acetylation, 
SUMOylation, ubiquitination and methylation(71). The importance of 
PTMs of the AR for male bone metabolism is unknown. SUMOylation is 
a reversible modification in which small ubiquitin-related modifier 
(SUMO) proteins are covalently attached to specific lysine residues, 
thereby regulating diverse cellular processes, including transcription, 
replication, chromosome segregation, and DNA repair(72,73). Substrate 
modification by SUMOylation can alter protein-protein interactions, 
change the intracellular localization of the protein, or directly change the 
activity of the protein to which SUMO is attached(71). There are three 
members of the SUMO protein family that can be conjugated to proteins: 
SUMO1, SUMO2 and SUMO3. SUMO2 and SUMO3 differ by only 
H Ligand Binding DomainDBDN-terminal Domain
Exon 1 2 3 4 5 6 7 8N’ C’
Exon Exon Exon Exon Exon Exon Exon
p q
q11-12
X Chromosome
AF-1 AF-2
Androgen Receptor
Figure 6. Androgen receptor domains. Adapted from “https://commons.wikimedia.org/wiki/File: 
Functional_domains_of_the_human_androgen_receptor.svg” by Wikimedia Commons. CC BY-SA 3.0. 
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three N-terminal residues and are often referred to collectively as 
SUMO2/3. In contrast, SUMO1 shares only 50% similarity with 
SUMO2/3(73). AR SUMOylation is a reversible process achieved by 
SUMO proteases termed Sentrin/SUMO-specific proteases (SENPs)(74). 
 
In humans, AR SUMOylation occurs within the N-terminal domain of 
AR at Lys386 (Lys381 in mouse) and Lys520 (Lys500 in mouse). In 
vitro experiments have established that reversible SUMOylation is a 
mechanism for regulation of AR function(74). The initial in vitro studies 
indicated that AR SUMOylation mainly reduced AR activity, while a 
subsequent more detailed functional in vitro study revealed that AR 
SUMOylation also may lead to increased AR-dependent transcription(74-
76). In the later study, the role of the two AR SUMOylation sites was 
evaluated by comparing cell lines expressing WT AR with cell lines 
expressing doubly SUMOylation site-mutated AR(76). Genome-wide gene 
expression analyses of these cell lines revealed that AR SUMOylation 
modulates the AR function in a target gene and pathway selective 
manner. Besides, SUMOylation mutant AR cells proliferated faster than 
WT cells. These data indicate that AR SUMOylation does not simply 
suppress the AR activity, but regulates the AR’s interaction with the 
chromatin and the receptor’s target gene selection. In addition, this might 
occur in a promoter specific and cell-type specific context(76). Further 
analysis of SUMOylation of AR should provide a better understanding of 
AR function in normal and diseases states and may lead to the discovery 
of novel therapeutic options. 
1.10 Androgens and bone 
Both androgens and estrogens are important for bone health in men. Men 
with inactive ERα or aromatase deficiency do not display any growth 
plate closure, demonstrating that estrogens have a dominant role in this 
process(77-81). Most of the effects of T on longitudinal bone growth are 
believed to be mediated via estrogens.  
 
During and shortly after puberty, boys develop wider bones due to 
greater periosteal bone apposition whereas the cortical endosteal 
perimeter is reduced in girls(20,21). The cortical bone in men is thereby 
placed further outward compared with women and this results in stronger 
bones in men than in women. The periosteal expansion is known to be 
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stimulated by androgens and inhibited by estrogens. An effect of 
androgens on periosteal bone expansion is supported by the observation 
that serum levels of free T were positively associated with the periosteal 
circumference at both the tibia and the radius in young men(82). 
 
Hypogonadal men with low T have low bone mass and increased risk of 
osteoporosis and fractures(83,84). Observational studies demonstrate that 
serum E2 and especially bioavailable E2 correlate better with BMD at 
various bone sites than serum T does in men(85-87). Furthermore, analyses 
of well-powered cohorts of elderly men with serum sex steroids analyzed 
by mass spectrometry demonstrate that serum E2 was inversely 
associated with the risk of fracture(88). In the MrOS Sweden cohort, low 
E2 but not low T was an independent predictor of fracture risk. The 
relation between bioavailable E2 and fracture risk was nonlinear and the 
fracture risk was clearly elevated below a specific E2 threshold (~12-16 
pg/ml)(88,89). In some prospective studies, low serum levels of T have 
been associated with a modest increase in fracture risk(90-92). This 
association has been proposed to be mediated via effects of T on muscle 
mass(93) and risk of falls(90). 
1.11 Androgens and bone - animal models 
Rodent models have been very important to investigate the cellular and 
molecular mechanisms of sex steroid actions in bone. However, some 
differences between rodents and humans need to be considered(94). 
Although rodents produce the androgen precursor androstenedione, they 
do not produce significant amount of DHEA in the adrenal glands(44). 
Furthermore, rodents do not express SHBG and the circulating levels of 
sex steroids are much lower in rodents compared with humans. Therefore 
sensitive and specific assays for serum sex steroid analyses in rodents are 
required(95). Alternatively, the weights of sex steroid sensitive 
reproductive tissues can be used as biomarkers of sex steroid status in 
rodents. In addition, the growth plates do not close directly after sexual 
maturation in rodent models.  
 
The effects of sex steroids on the skeleton have been widely studied in 
rodents by gonadectomy followed by hormone replacement therapy, and 
by administration of AR antagonists, ER antagonists, aromatase 
inhibitors, SARMs, selective estrogen receptor modulators (SERMs) and 
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type II 5α-reductase inhibitors. In male rodents, orchidectomy increases 
bone turnover and bone resorption is increased more than bone 
formation, resulting in trabecular and cortical bone loss(96-98).  
 
The importance of sex steroid receptors has further been studied using 
different mouse models. Male testicular feminization (Tfm) mice have a 
non-functional AR and a high bone turnover phenotype(99). Furthermore, 
several ubiquitous male ARKO mouse models have been developed and 
they all exhibit low bone mass and high bone turnover, which is 
consistent with the effects of androgen deficiency(100-105). Cell-specific 
ARKO mice models have revealed that AR signaling in osteoblasts is 
responsible for the protective effects of androgens on trabecular bone 
mass whereas the target cell(s) for the effects of AR on cortical bone 
mass remain unknown(101,106-108). Although all these different ARKO 
mouse models have been informative, they all lack AR expression since 
the time of conception and it is therefore not possible to determine if the 
observed effects are developmental or not. Furthermore, the primary 
target cell for the effects of androgens on cortical bone mass remains to 
be identified. 
1.12 Prostate cancer  
Prostate cancer (PC) is the most common type of cancer for men in Swe-
den. Localized PC may be treated with surgery (radical prostatectomy) or 
radiation therapy. The role of androgens for PC was first demonstrated in 
1941 by Huggins, who showed that surgical castration, removing testicle-
derived androgens, reduced tumor size and tumor symptoms(109). Since 
then, surgical or chemical ADT is the first treatment of metastatic PC. 
Unsurprisingly, ADT is associated with bone loss and increased risk of 
bone fractures(94,110).  
1.13 Androgen deprivation therapy (ADT) and 
AR antagonists 
ADT, using surgical or chemical castration, is a standard treatment for 
metastatic PC. The goal of the treatment is to reduce the levels of 
androgens in the body and thereby block the growth of prostate cancer 
cells. Chemical castration i.e. gonadotropin-releasing hormone (GnRH) 
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agonists or antagonists, targets the hypothalamic-pituitary-gonadal 
axis(111). Administration of GnRH agonists results in downregulation of 
the pituitary receptors for GnRH, leading to suppression of FSH and LH 
and thereby the testicular production of T is suppressed(112). GnRH 
agonists have become the standard first-line hormonal treatment in 
patients with metastatic PC(112). Beside the testes, the adrenal gland and 
prostate cancer cells may also synthesis androgens or androgen 
precursors. This non-testicular androgen synthesis, not affected by ADT, 
can be inhibited by use of CYP17α hydroxylase inhibitors such as 
abiraterone acetate that inhibits a key step in the synthesis of 
androgens(113,114). The conversion of DHT from T can be inhibited by 5α 
reductase inhibitors (such as finasteride), but this treatment is only used 
to shrink the enlarged prostate in benign prostatic hyperplasia(115).  
 
Although many patients respond to ADT initially, they often relapse as 
they develop a castration-resistant prostate cancer (CRPC) state(116). The 
mechanisms behind CRPC are not fully understood, but it is apparent that 
signaling via the AR often continues to be crucial for prostate tumor 
growth despite low circulating levels of T. Besides local androgen 
synthesis by the PC cells, hypersensitive ARs as a result of AR mutations 
have been demonstrated in CRPC cells(117-119). Therefore, it may still be 
worth targeting the AR signaling pathway by use of AR antagonists (also 
called antiandrogens) in the treatment of CRPC. First-generation 
antiandrogens (e.g. bicalutamide, nilutamide, flutamide) block the 
androgen-binding site of the AR whereas second-generation 
antiandrogens have a wider range of mechanisms. Enzalutamide and 
apalutamide are both second-generation, nonsteroidal 
antiandrogens(120,121). They affect the AR signaling pathway in at least 
three different ways: they bind to the AR with great affinity, reduce the 
efficiency of AR nuclear translocation, and impair both DNA binding to 
androgen response elements and recruitment of coactivators(120,121). En-
zalutamide is given to patients with metastatic CRPC either before(122) or 
after chemotherapy(123). However, since July 2018, enzalutamide is ap-
proved by the U.S. Food and Drug Administration (FDA) for the treat-
ment also of non-metastatic CRPC (nmCRPC)(124). Apalutamide has also 
recently been approved by the FDA as a treatment for patients with 
nmCRPC(125). The side effects of these second-generation nonsteroidal 
antiandrogens on the skeleton are unclear. 
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1.14 Selective androgen receptor modulators 
(SARMs) 
A recent randomized placebo-controlled study demonstrated that T 
treatment increased volumetric BMD in men with slightly low serum 
T(126). T treatment of men with severe hypogonadism results in increased 
sexual function, increased energy, slightly increased muscle mass, 
decreased fat mass, increased bone mineral density and increased 
hemoglobin levels(127,128). However, treatment with T may lead to side 
effects such as an increased risk of cardiovascular diseases, increased risk 
of prostate cancer and very high levels of hemoglobin. Therefore, 
increased knowledge about the tissue-specific signaling mechanisms of 
androgens via the AR is needed for possible development of bone-
specific SARMs with minimal side effects in other tissues. SARMs have 
been proposed as possible specific treatments for muscle-wasting and 
osteoporosis in men(129). SARMs were first described and subsequently 
developed by Dalton et al in 1998(130). Most of the SARMs developed 
thus far are non-steroidal and have the ability to activate the AR in 
muscle and bone(129,131). Although there are ongoing clinical trials there is 
not yet any FDA or EMA approved SARM on the market.  
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2. Aims 
The overall aim of this thesis was to increase the knowledge about the  
significance of the AR for bone metabolism to potentially identify bone-
specific AR signaling pathways.  
	
Specific aims 
 
1. To evaluate the importance of the AR in immature osteoblast-
lineage cells for trabecular and cortical bone mass in males (Paper I) 
 
 
2. To characterize the effects of enzalutamide, an AR antagonist used 
in the treatment of prostate cancer, on bone metabolism (Paper II) 
 
 
3. To determine the importance of the AR for adult bone metabolism, 
avoiding confounding effects during development (Paper III) 
 
 
4. To elucidate the importance of SUMOylation of the AR for male 
bone metabolism (Paper IV) 	  
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3. Methodological considerations  
3.1 Animal models 
Mice are commonly used as models for studying different human diseas-
es and treatments. They are inexpensive to breed since the generation 
time and lifespan are relatively short. Furthermore, the mouse genome is 
rather similar to the human genome and it can be manipulated relatively 
easily. Therefore, mouse models lacking or overexpressing certain genes 
can be developed and studied easily. In this thesis, the importance of the 
AR for bone metabolism is studied by use of the following different 
mouse models (Figure 7):   
 
Paper I: Genetic inactivation of the AR specifically in osteoblast-lineage 
cells by use of a cell-specific Cre recombinase.  
Paper II: Treatment with the AR antagonist enzalutamide. 
Paper III: Inducible genetic inactivation of the AR by use of a tamoxi-
fen-dependent Cre recombinase. 
Paper IV:  Genetic modulation of the AR SUMOylation sites K381R 
and K500R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Illustration of the AR modifications used in this thesis. Adapted from “https://commons. 
wikimedia.org/wiki/File:Functional_domains_of_the_human_androgen_receptor.svg” by Wiki-
media Commons. CC BY-SA 3.0. 
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3.1.1. Cre-loxP recombination system 
The Cre-loxP recombination is a site-
specific recombinase technology, used to 
achieve deletions, insertions, translocations 
and inversions at specific sites in the DNA 
of cells(132-134). The Cre recombinase is a 38 
kDa protein that is capable to recognize loxP 
sites, composed of two 13 bp inverted 
repeats interrupted by an 8 bp 
nonpalindromic sequence, in the genome. Cre-mediated recombination 
between two loxP sites results in the excision of the loxP-flanked, or 
“floxed,” DNA sequence. In Papers I and III, we mated genetically modi-
fied female mice heterozygous for the floxed exon 2 of the AR gene 
(AR+/flox) with different male mouse models expressing the Cre (Figure 
8)(135). In Paper I, the expression of Cre recombinase was driven by the 
osterix (Osx1 or Sp7) promoter (#006361, the Jackson Laboratory)(136). In 
male ARflox mice expressing Osx1-Cre, the Cre recombinase is expressed 
from the osteoprogenitor stage resulting in deletion of AR in osteopro-
genitors as well as osteoblast precursors, mature osteoblasts, and osteo-
cytes that all stem from the osteoprogenitors. These osteoblast-lineage 
cell-specific ARKO mice were called O-ARKO mice. Due to effects on 
the skeleton and body weight in Osx1-Cre transgenic mice(137,138), Osx1-
Cre expressing littermates without the ARflox construct were used as con-
trols.  
 
In Paper III, the Cre recombinase-expressing transgenic mice are called 
CAG-CreER mice (#004682, the Jackson Laboratory)(139). These CAG-
CreER transgenic mice express a tamoxifen-inducible Cre-mediated re-
combination system driven by the chicken beta actin promoter/enhancer 
coupled with the cytomegalovirus (CMV) immediate-early enhancer. The 
CreER fusion protein consists of Cre recombinase fused to a G525R mu-
tant form of the mouse estrogen receptor (ER), which does not bind its 
natural ligand (17β-estradiol) at physiological concentrations but will 
bind the synthetic ER ligand tamoxifen. The CreER fusion protein is re-
stricted to the cytoplasm but after exposure to tamoxifen, it gains access 
to the nuclear compartment. Upon translocation to the nucleus the CreER 
fusion protein excises the floxed exon 2 of the AR (Figure 9). In Paper 
III, the AR was inactivated in an inducible manner at the age of 4 or 10 
weeks.  
 
Figure 8 AR+/flox mice with exon 2 
of AR flanked by loxP sites. 
DBD
2 3
loxP loxP
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Although this Cre transgenic system is well studied and known to have 
low background Cre activity in the absence of an inducer, previous re-
ports indicate that the use of the tamoxifen-inducible Cre-loxP system is 
not without potential drawbacks(140,141). Using correct controls are there-
fore fundamental. In Paper III, CAG-CreER expressing littermates with-
out the ARflox construct were used as controls. Furthermore, tamoxifen is 
a SERM that has been reported to affect the skeleton(142,143). The possible 
confounding effects of tamoxifen on the skeleton in Paper III were 
avoided by the fact that the control mice received the same dose of ta-
moxifen as the inducible ARKO mice. 
3.1.2. The ARSUM- mouse model  
The AR is activated by binding of a ligand, but the function of the AR is 
further regulated by PTMs, such as phosphorylation, ubiquitination and 
SUMOylation(144). When the AR is SUMOylated, small ubiquitin-related 
modifier proteins are covalently attached to two conserved lysine 
residues at the N-terminal transactivation domain of the AR. In humans, 
the SUMOylation sites of the AR are the lysine (K) at positions 386 and 
520, corresponding to positions 381 and 500 in the mouse genome(74). To 
be able to study the importance of SUMOylation of the AR for bone 
metabolism (Paper IV), we have used the ARSUM- mouse model, recently 
developed by our collaborators Prof. Poutanen and Prof. Palvimo at the 
University of Turku, Finland. The ARSUM- 
mouse model is a knock-in mouse model in 
which the conserved lysines in the N-
terminal domain of the AR were 
permanently abolished by converting them 
to arginines (R) (K381R, K500R) (Figure 
10). Thereby, SUMOylation of the AR is 
blocked in this mouse model.  
Figure 9 Schematic illustration of the strategy for induced AR inactivation by tamoxifen. 
Figure 10  AR SUMOylation is 
inhibited by lysine to arginine muta-
tions at SUMO sites.  
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3.2 Dual-energy X-ray absorptiometry (DXA) 
Dual-energy X-ray absorptiometry (DXA) is the most frequently used 
approach for bone mineral density measurement in both clinical practice 
and animal research. It is a non-invasive method, which is an advantage 
when longitudinal studies are performed.  Due to the two emitted X-ray 
beams with different energy levels, the DXA can distinguish between 
bone and soft tissue, since these tissues absorb energy differently. 
However, one important disadvantage with the DXA technique is that the 
images produced are two-dimensional (2D). The DXA, therefore, only 
recognizes changes in length and width and does not account for changes 
in the third dimension, which might become a problem when examining 
growing animals with major skeletal changes in size. The areal bone 
mineral density (aBMD; g/cm2) as determined by DXA should not be 
mistaken for true volumetric BMD (vBMD; g/cm3). In Papers I-III, DXA 
measurements were performed on all mouse models directly before 
termination using the Lunar PIXImus mouse densitometer (Wipro GE 
Healthcare, Madison, WI, USA) with a pixel size of 500 µm. 
3.3 Micro-computed tomography (µCT) 
Micro-computed tomography (µCT) is a non-invasive imaging technique 
for detailed bone analysis. In contrast to DXA, µCT uses X-ray 
attenuation data acquired at multiple viewing angles to reconstruct a 
three-dimensional (3D) representation of the bone that characterizes the 
spatial distribution of material density(145,146). The µCT can separate 
the trabecular bone from cortical bone and also provides the bone 
dimensions. Currently available µCT scanners achieve an isotropic voxel 
size as low as a few µm, which is sufficient to investigate bone 
microstructures such as trabecular bone microstructure and cortical 
porosity in mice. Therefore, µCT has become the “gold standard” for ex 
vivo evaluations of bone morphology and microarchitecture of the 
skeleton in mouse models and other small animal models.  
 
The ex vivo bone sample is placed on a rotating stage between an X-ray 
generator and a charge-coupled detector (CCD) array. X-rays pass 
through the sample and the radiograph is recorded by the detector. The 
sample is rotated and another projection is taken at the new position. The 
procedure is repeated until the sample has rotated 180 degrees and a 
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complete set of radiographs has been produced. The set of X-ray 
projection images is then computed into 2D cross-sectional images 
through the computational process called reconstruction. The individual 
2D slices are stacked to create a 3D volume used for quantitative 
analyses, such as bone volume/total volume (BV/TV), trabecular 
thickness (Tb.Th), trabecular number (Tb.N), trabecular separation 
(Tb.Sp), cortical thickness (Ct.Th), and cortical porosity (Ct.Po). In 
Papers I-IV, a SkyScan 1172 scanner (Bruker, Aartselaar, Belgium) with 
voxel size of 4.5 µm was used for µCT analyses. 
3.4 Biomechanical testing 
Although µCT analysis can reveal detailed information on bone structure 
in three dimensions, destructive three-point bending (long bones) and 
compression testing (vertebrae) provide important biomechanical 
parameters of bone strength and toughness. Determination of the 
mechanical properties by three-point bending of the long bones is 
performed by positioning the bone horizontally on two supports, and 
applying a single-pronged loading device to the opposite surface at a 
point precisely in the middle of the two supports(147). A gradually 
increased force is applied until the bone eventually breaks. During this 
process, the stress-strain responsive curve of the bone is measured. 
Initially, the relationship between the force exerted on the bone and the 
strain of the bone is linear and this linear slope corresponds to the 
stiffness of the bone. The force applied when the bone breaks is the 
maximum load, given in the unit Newton. In Papers II-IV, biomechanical 
testing of the long bones was performed using the Instron 3366 
biomechanical testing machine (Instron Corp., Norwood, MA, USA).  
 
In contrast to the three-point bending test that mainly measures the 
cortical bone strength, the compression test is commonly used to assess 
the biomechanical properties of the trabecular bone, which is present in 
large quantities in the vertebrae. During the compression test in Paper II, 
the intact vertebrae were axially loaded using the above mentioned 
Instron 3366 testing machine, measuring the stress-strain response curve 
of the vertebral body.  
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3.5 Histomorphometric analyses 
While high-resolution imaging techniques such as µCT can provide 
information about bone mass and bone structure, they cannot provide 
information regarding the cellular composition and the bone formation in 
the bone. This can instead be analyzed by bone histomorphometry. After 
fixation, dehydration, and defatting in xylene, the undecalcified bones are 
embedded in a plastic resin. It is important that the density of the resin 
and bone are closely matched. For static analyses of the bones, 4 µm 
thick sections were stained with Masson-Goldner trichrome whereas 
unstained 8 µm thick sections were analyzed for dynamic parameters. 
Static analyses of trabecular bone included parameters such as bone 
volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular 
number (Tb.N) and trabecular separation (Tb.Sp); whereas in cortical 
bone analyses, total bone area (B.Ar), marrow cavity area (Ma.Ar), and 
cortical bone area (Ct.Ar) can be studied. Furthermore, the number and 
surface area of osteoblasts, and osteoclasts on bone surfaces as well as 
osteocyte density within the bone can be analyzed.  
 
Dynamic parameters of bone formation such as mineral apposition rate 
and mineralized surface per bone surface are analyzed by using the 
fluorescent markers. One and eight days before sacrifice, the mice were 
labeled with intraperitoneal injections of the fluorochromes calcein or 
alizarin. These compounds are calcium-seeking substances that are 
incorporated into the mineralization front of mineralizing surfaces, which 
can then be visualized in histological specimens by their fluorescence 
under excitation with ultraviolet (UV) light.  
3.6 Serum measurements 
Bone turnover can also be assessed by measurement of formation and 
degradation products of bone matrix elements in the serum. In Papers I-
III, commercially available enzyme-linked immunosorbent assays 
(ELISAs) were used to measure serum osteocalcin, a marker for bone 
formation, and serum CTX-I, which is a bone-related degradation 
product from C-terminal telopeptides of type I collagen. 
 
Serum levels of sex steroids were measured in Papers II-IV by gas 
chromatography-tandem mass spectrometry (GC-MS/MS). This method 
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was recently established by co-workers at the Centre for Bone and 
Arthritis Research(95). In contrast to earlier available sex steroid 
measurement methods, this newly developed GC-MS/MS method is 
highly sensitive and specific for E2, E1, T, DHT, progesterone, 
androstenedione, and DHEA. This method is an improvement over 
previous methods for measuring sex steroid levels in rodents and 
represents a valuable contribution with respect to reference intervals in 
mice. 
3.7 DNA and RNA quantification 
The efficacy and specificity of the cell- and time-specific AR knockouts 
in Paper I and III, respectively, were analyzed by real-time quantitative 
PCR(148). The real-time qPCR technique allows quantification of the gene 
of interest by use of a pair of specific oligonucleotides as primers in the 
reaction. Added in the reaction is also a fluorochrome that fluoresces 
when excited. 
 
In Paper I, the efficacy and specificity of the AR knockout (O-ARKO) in 
the osteoblasts were analyzed at the DNA level. Genomic DNA was 
prepared from the cortical bone of femur, spleen, bone marrow, thymus, 
liver, kidney, aorta, heart, skin, and testis. The O-ARKO mice have, as 
described above, a floxed exon 2, and in cells expressing Cre 
recombinase, exon 2 of the AR is deleted. In the real-time qPCR reaction, 
primers specific for DNA sequences within the exon 2 vs. exon 3 were 
used for relative quantification. The fluorochrome in this reaction was 
SYBR green, which fluoresces when bounds to double-stranded DNA. 
 
In Paper III, AR inactivation was analyzed by measurement of the AR 
mRNA levels in different tissues. Using this method, total RNA was 
prepared and further transcribed into complementary DNA (cDNA). Pre-
designed primers complementary to the cDNA sequence of interest was 
included in the reaction and amplification was then related to an internal 
standard. For the mRNA expression analyses, sequence-specific 
fluorophore labelled TaqMan probes were used. Expression of other 
genes of interest such as Cathepsin K and collagen type 1 alpha 1, was 
analyzed by the same method. 
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In Paper IV, real-time PCR analysis was used to examine if there was any 
change in AR mRNA levels after replacing two amino acids in the AR. 
3.8 Western blot 
In order to investigate the AR protein levels in different tissues following 
inactivation of SUMOylation sites of AR in Paper IV, Western blot was 
performed. Western blot is extensively used for qualitative detection of 
single proteins in a mixture and a semi-quantitative estimation of protein 
levels can be achieved. Denatured proteins were size-separated by gel 
electrophoresis followed by electrophoretic transfer onto a blot 
membrane. The AR protein was detected by incubation with a specific 
primary antibody followed by a TidyBlot HRP (horseradish peroxidase) 
conjugated detection reagent and Clarity Max Western ECL (enhanced 
chemiluminescence) substrate. The visualization was performed using a 
ChemiDoc System (Bio-Rad, Hercules, CA, USA). GAPDH 
(Glyceraldehyde-3-phosphate dehydrogenase) is constitutively expressed 
in almost all tissues in high amounts and for this reason, it was used as a 
loading control. 
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4. Results 
Below is a brief description and summary of the results of the four papers 
included in the thesis. For more details, see the full papers at the end of 
the thesis. 
4.1 Paper I 
Androgens regulate bone marrow B lymphopoiesis in male mice by tar-
geting osteoblast-lineage cells  
 
In this study we evaluated the importance of the AR in immature osteo-
blast-lineage cells for trabecular and cortical bone mass in young adult 
male mice.  
 
We specifically deleted the AR in immature osteoblast-lineage cells by 
mating ARflox mice with Osx1-Cre mice. Osx1-Cre is expressed in the 
osteoprogenitor stage and as a result, the AR is deleted in the osteoblast-
lineage starting already at the osteoprogenitor stage(136).  
 
Mice with no expression of the AR in immature osteoblast-lineage cells 
(O-ARKO) displayed significantly affected trabecular bone in the verte-
brae, reflected by reduced trabecular number. In contrast, the cortical 
bone mass was unaffected. Furthermore, the serum levels of both the 
bone formation marker osteocalcin and the bone resorption marker CTX-
I were significantly increased in O-ARKO mice compared with WT 
mice. This suggests an elevated bone turnover in these mice compared 
with WT mice. 
 
In conclusion, AR deficiency in osteoblast-lineage cells reduced the tra-
becular number in vertebrae, whereas cortical bone mass was unaffected, 
supporting the notion that the AR in osteoblast-lineage cells is involved 
in the regulation of trabecular but not cortical bone homeostasis. 	  
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4.2 Paper II 
Enzalutamide reduces the bone mass in the axial but not the appendicu-
lar skeleton in male mice 
 
In this study, we evaluated the effect of enzalutamide, an AR antagonist 
used in the treatment of prostate cancer, on adult bone metabolism.  
 
Nine-week-old WT male mice were treated with 10, 30, or 100 mg/kg·d 
of enzalutamide for 21 days or were surgically castrated (ADT) and were 
compared with vehicle-treated gonadal intact mice. The effects on the 
skeleton and on several other androgen-responsive tissues were evaluat-
ed. 
 
While orchidectomy (orx) reduced the cortical bone thickness and tra-
becular bone volume fraction in the appendicular skeleton, these parame-
ters were unaffected by enzalutamide. In contrast, both enzalutamide and 
orx reduced the bone mass in the axial skeleton as demonstrated by re-
duced lumbar spine areal BMD (p<0.001) and trabecular bone volume 
fraction in L5 vertebrae (p<0.001) compared with vehicle-treated gonadal 
intact mice. A compression test of the L5 vertebrae revealed a significant-
ly reduced maximal load at failure by enzalutamide treatment, demon-
strating a reduced mechanical strength in the axial skeleton induced by 
enzalutamide treatment. The bone loss in the axial skeleton by enzalu-
tamide treatment was associated with a high bone turnover. 
 
We conclude that enzalutamide reduces the bone mass in the axial but not 
the appendicular skeleton in young adult male mice. Surgical castration, 
affecting both estrogenic and androgenic pathways in bone, increases the 
risk of both vertebral and non-vertebral fractures in males, whereas our 
present findings suggest that antiandrogen treatment with enzalutamide 
may increase vertebral but not non-vertebral fracture risk in PC patients.  	  
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4.3 Paper III 
The androgen receptor is required for maintenance of bone mass in adult 
male mice 
 
In this study, we determined the importance of the AR for pubertal and 
adult bone homeostasis.  
 
The AR was conditionally ablated at four (pre-pubertal) and ten (post-
pubertal) weeks of age in male mice using tamoxifen-inducible Cre-
mediated recombination of CAG-CreER;ARflox/y mice. At four and ten 
weeks of age, tamoxifen was administered i.p. for three or four consecu-
tive days, respectively (50 mg/mouse/day). CAG-ARflox/y mice did not 
have any bone phenotype and, therefore, tamoxifen treated CAG-
CreER;ARflox/y mice were compared with tamoxifen-treated CAG-
CreER;AR+/y control mice at 14 weeks of age.  
 
Both the pre-pubertal and the post-pubertal AR inactivation were effi-
cient as demonstrated by substantially lower AR mRNA levels in seminal 
vesicles, bone and white adipose tissue as well as markedly reduced 
weights of reproductive tissues when comparing the inducible ARKO 
mice and control mice at 14 weeks of age. Serum T levels were not af-
fected by post-pubertal AR inactivation while pre-pubertal AR inactiva-
tion resulted in increased serum T levels. Both pre- and post-pubertal AR 
inactivation increased serum DHT levels resulting in significantly in-
creased serum DHT/T ratios associated with increased expression of 
Srd5a2, encoding 5α-reductase type 2, in the seminal vesicles. These 
findings indicate that the synthesis of the potent androgen DHT by 5α-
reductase type 2 is subject to local negative feed-back regulation mediat-
ed by the AR. Total body BMD, as analyzed by DXA, as well as tibia 
diaphyseal cortical bone thickness and proximal metaphyseal trabecular 
bone volume fraction, as analyzed by µCT, were significantly reduced by 
both pre-pubertal and post-pubertal AR inactivation. These bone effects 
were associated with increased bone turnover, indicating high bone turn-
over osteoporosis. Pre-pubertal but not post-pubertal AR inactivation re-
sulted in substantially increased fat mass. 
 
In conclusion, AR is required for maintenance of both the trabecular and 
cortical bone in adult male mice. By comparing pre-pubertal and post-
pubertal AR inactivation, we conclude that adult AR expression is crucial 
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for trabecular and cortical bone mass maintenance while pubertal AR 
expression is crucial for normal fat mass homeostasis in adult male mice. 
4.4 Paper IV 
 
Androgen receptor SUMOylation regulates bone mass in male mice  
 
In this paper, we elucidate the importance of SUMOylation of the AR for 
adult male bone metabolism. 
 
We generated a mouse model devoid of two of the AR SUMOylation 
sites (ARSUM- mice) by introducing two point mutations, K381R and 
K500R (two lysine residues mutated to arginine) and evaluated the skele-
tal phenotype. 
 
Six-month-old ARSUM- mice displayed normal body weight and had nor-
mal serum T levels. In addition, the weights of two well-established an-
drogen-responsive tissues, seminal vesicles and the muscle levator ani, 
were not significantly altered. Male ARSUM- mice displayed significantly 
reduced trabecular bone volume fraction in the distal metaphyseal region 
of femur compared with WT mice. The number of osteoblasts per bone 
perimeter was substantially reduced while no significant effect was ob-
served on the number of osteoclasts in the trabecular bone of male 
ARSUM- mice compared with WT mice. The bone formation rate was re-
duced as a result of reduced mineralizing surface per bone surface in 
ARSUM- mice compared with WT mice. Finally, there was a moderate 
reduction in the cortical bone thickness in the diaphyseal region of femur 
in male ARSUM- mice compared with WT mice. 
 
We conclude that mice devoid of AR SUMOylation have reduced trabec-
ular bone mass as a result of reduced bone formation. We propose that 
therapies enhancing AR SUMOylation might result in bone-specific ana-
bolic effects with minimal adverse effects in other tissues. 
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5. Discussion 
5.1 AR expression in immature osteoprogenitor 
cells affects trabecular but not cortical bone 
It is clear that the AR plays an important role for the homeostasis of the 
male skeleton since both men with hypogonadism and men with com-
plete androgen insensitivity syndrome because of a loss-of-function mu-
tation in the AR, have low bone mass(83,149).  In addition, experimental 
mouse studies demonstrate that global deletion of the AR in male mice 
results in decreased trabecular as well as cortical bone mass due to high 
bone turnover and increased bone resorption(100,102). However, although 
these global AR knockout mouse models have provided important in-
sights, mice	ubiquitously lacking the AR also have significant reductions 
in circulating T levels. Therefore, it has been unclear whether the reduced 
bone mass in these mouse models is the result of loss of AR expression in 
bone cells, or the concomitant hypogonadism.  
 
More conclusive data for the role of the AR in bone metabolism have 
come from studies using the Cre-loxP technology for cell-specific 
deletions. A number of studies have used different osteoblast-lineage 
specific Cre models to delete the AR at different stages of osteoblast 
differentiation(150), by crossing transgenic mice expressing the Cre 
recombinase specifically under the control of either the collagen 1α1- 
(Col1α1-), osteocalcin- (Ocn-) or dentin matrix acidic phosphoprotein 1- 
(Dmp1-) promoter, with floxed AR mice. It has been demonstrated that 
deletion of the AR in mature osteoblasts or osteocytes results in 
osteopenia and increased bone resorption in trabecular, but not in cortical 
bone, of male mice(101,106-108). However, these findings do not exclude the 
possibility that the effects of androgens on cortical bone mass may be 
mediated via AR signaling in immature osteoprogenitor cells.  
 
To evaluate the hypothesis that AR expression in immature 
osteoprogenitor cells is important for the cortical bone homeostasis, the 
AR gene was in Paper I deleted by crossing transgenic mice expressing 
Cre recombinase under the control of the osterix promoter with floxed 
AR mice (O-ARKO). Osterix is a critical transcription factor essential for 
early osteoblast differentiation(151). In contrast to collagen 1α1, 
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osteocalcin and dmp1, osterix is expressed by the immature 
osteoprogenitor cells, which is earlier in the differentiation process of 
osteoblasts compared to when the other genes are expressed.  
 
The male O-ARKO mice displayed trabecular bone loss due to reduced 
trabecular number. In addition, analyses of serum markers for bone 
formation and bone resorption demonstrated that the O-ARKO mice had 
a high bone turnover. Moreover, neither cortical thickness nor cortical 
volumetric BMD was affected in the O-ARKO mice. The results from 
Paper I are consistent with the results from the earlier publications(101,106-
108), demonstrating that AR in osteoblast-lineage cells is specifically 
important for the trabecular bone mass. Furthermore, data from Paper I 
add to previous results that AR expression neither in immature early 
osteoprogenitor cells nor in mature osteoblast-lineage cells has an impact 
on cortical bone mass.  
 
Shortly after Paper I was published, Ucer et. al published an article 
describing an experiment in which they had crossed AR flox mice with 
mice expressing the Cre recombinase under the control of regulatory 
elements of the paired related homeobox 1 (Prx1) gene(152). This 
transgene is expressed in pluripotent mesenchymal progenitors and their 
progeny in the appendicular, but not the axial, skeleton(153). The results 
from the study performed by Ucer et. al confirmed the results in Paper I, 
demonstrating that AR expression in immature osteoprogenitor cells are 
not important for the cortical bone mass(152). 
 
Taken together, six separate studies clearly demonstrate that the anti-
resorptive effects of androgens on trabecular but not cortical bone result 
from AR-mediated actions in osteoblast-lineage cells. The fact that 
expression of AR in osteoblast-lineage cells is not important for the 
cortical bone is to some extent unexpected since there is a well-
established effect of androgens on cortical bone mass and larger cortical 
bone dimensions are observed in males compared to females. 
 
The target cell for AR-mediated effects on cortical bone mass remains to 
be identified and several attempts to solve this question have been done. 
The AR gene has been deleted in osteoclast-lineage cells by crossing 
LysM-Cre or Ctsk-Cre expressing mice with floxed AR mice but with no 
effect on neither cortical nor trabecular bone(152,154). This indicates that 
the target cells for the AR action on cortical bone mass are outside the 
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bone. It has been suggested that the effects of AR on the cortical bone 
mass may be indirect via effects on cells within the bone marrow, muscle 
cells or nerve cells. But further studies investigating the primary target 
cells of importance for AR actions in cortical bone are clearly 
warranted(94,155,156).                                                                     
5.2 Effects of enzalutamide on bone 
Prostate cancer is the most common type of cancer for men in Sweden 
and it is the second most frequently diagnosed cancer for men 
worldwide(157). Recommended treatments vary depending upon the stage 
of the disease, but ADT via surgical or medical castration is commonly 
used for metastatic prostate cancer(158). The endocrine treatments of 
prostate cancer either lower the androgen levels (ADT or abiraterone) or 
directly block the AR activity (antiandrogens such as enzalutamide).  
 
Although skeletal side effects have been reported for ADT(94,110), skeletal 
side effects of the newly approved second generation antiandrogens have 
not yet been thoroughly investigated. In Paper II we compared the 
skeletal side effect of the recently introduced antiandrogen enzalutamide 
and ADT using surgical castration in male mice. The three different 
doses of enzalutamide used were in the same range as previously used in 
different prostate cancer studies(120,159). Enzalutamide treatment 
substantially reduced the weight of androgen responsive tissues, 
confirming the antiandrogen effects of the treatment.  
 
The skeletal side effects of surgical castration were more pronounced, 
with substantially reduced bone mass in both the axial and the 
appendicular skeleton, compared with enzalutamide treatment that 
reduced the bone mass only in the axial skeleton. All three doses of 
enzalutamide treatment clearly reduced the lumbar spine aBMD, 
suggesting that AR-mediated effects are crucial for the maintenance of 
adult bone mass in the axial skeleton. The effect of enzalutamide on the 
trabecular bone mass in vertebrae was confirmed by µCT and 
histomorphometric analyses, revealing that the inhibitory effect of 
enzalutamide on trabecular bone volume fraction was mainly the result of 
reduced trabecular number. Moreover, high dose enzalutamide treatment 
reduced the compressive bone strength of vertebrae to the same extent as 
surgical castration. In general, the more pronounced effect on bone mass 
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of surgical castration compared with enzalutamide treatment is most 
likely due to reductions in both T and E2 production after surgical 
castration, consequently leading to less stimulation of both the AR and 
ERα. In contrast, enzalutamide treatment only inhibits the actions via the 
AR. The ERα-mediated effects are important for the regulation of the 
bone mass in both the appendicular and the axial skeleton, demonstrated 
by previous studies using aromatase inhibitors, aromatase inactivation 
and ERα inactivation(94,103,160). 
 
A limitation with the present study is that the efficiency of AR blockage 
in the different bone compartments by enzalutamide treatment was not 
measured. Therefore, one cannot exclude the possibility that the AR 
blockage in the appendicular skeleton might be more incomplete as 
compared with the AR blockage in the axial skeleton, contributing to the 
site-specific effects of enzalutamide. Furthermore, since the mice in our 
study were treated only for 21 days, one cannot rule out the possibility 
that prolonged treatment, mimicking the clinical situation, might also 
affect the appendicular skeleton(122,123,161).  
 
Currently, enzalutamide is given as an additional treatment to patients 
with metastatic CRPC either before(122) or after chemotherapy(123). In July 
2018, enzalutamide was also approved by the FDA for the treatment of 
nmCRPC(124). Thereby, enzalutamide is the first and only FDA-approved 
oral medication for both non-metastatic and metastatic CRPC. The 
updated label was based on results from the Phase 3 PROSPER trial, 
which demonstrated that the use of enzalutamide plus ADT significantly 
reduced the risk of developing metastasis or death compared to ADT 
alone in men with nmCRPC(162). 
 
The expanded indication of the AR antagonist enzalutamide to chemical-
ly castrated patients, who are already depleted of the testicular-derived 
androgens, might not substantially increase the risk of vertebral fractures 
beyond the chemical castration effect. However in monotherapy, as en-
zalutamide also blocks the effects of adrenal-derived androgens, bone 
mass in the axial skeleton might be further reduced and increasing the 
risk of vertebral fractures compared with other treatments. A recent clini-
cal phase 2 study of enzalutamide monotherapy in hormone-naïve pros-
tate cancer of varying severity revealed that this treatment substantially 
reduced PSA levels, suggesting that enzalutamide monotherapy might, in 
the future, be considered as an early treatment also for men with hor-
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mone-naïve prostate cancer(163). Longitudinal BMD measurements by 
DXA were recently available in a small cohort of men treated with en-
zalutamide monotherapy for three years but no significant reduction in 
BMD was observed in this limited dataset with no placebo treated control 
group to compare(161). The trend of minor decreases in BMD after three 
years of enzalutamide treatment in that study were less pronounced than 
the BMD decreases previously reported for long-term ADT(164-166). 
 
5.3 Presence of a functional AR in adult mice is 
required to maintain trabecular and cortical bone 
mass  
One of the major concerns of the different models with global or cell-
specific deletion of AR is that they all lack expression of the AR already 
since the time of conception. Therefore, from these models, it is 
impossible to elucidate the relative role of AR during development, 
sexual maturation and in adult mice. Likely, lack of AR expression 
during early development results in imprinting effects with health 
consequences later in life as well as development of redundant 
mechanisms that confound the interpretation of the role of the AR during 
adult life(167). Also, global deletion of the AR since time of conception 
affects the testicular development causing hypogonadism with low serum 
T levels(100,102). 
 
To overcome these problems and to be able to determine the importance 
of the AR specifically during sexual maturation and in adult male mice, 
an inducible knockout model system is required. Since 1995, when Kühn 
et al introduced an inducible inactivation of a target gene(168), different 
inducible knockout model systems have been developed, such as 
tetracycline- and tamoxifen-inducible systems(169,170). The tamoxifen-
induced system permanently manipulates the gene of interest. In the 
tamoxifen-induced mouse model, the Cre recombinase only enters the 
nucleus when tamoxifen is present and the deletion of the gene can be 
induced by systemic tamoxifen injections at time points selected by the 
investigator.   
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In Paper III of this thesis we used the tamoxifen-inducible system and 
developed mouse models with either pre-pubertal or post-pubertal AR 
inactivation.  Efficient recombination was confirmed for both pre-
pubertal and post-pubertal AR inactivation, demonstrated by decreased 
AR mRNA expression level in seminal vesicles and bones. Both pre-
pubertal and post-pubertal AR inactivation reduced the trabecular as well 
as the cortical bone mass, mimicking the skeletal effects observed 
following life-long global AR inactivation(100,102). These results clearly 
demonstrate that adult post-pubertal AR expression is required for 
maintenance of both the trabecular and cortical bone mass.  
 
The reduced bone mass by inducible AR inactivation was associated with 
increased bone resorption, as demonstrated by elevated serum levels of 
the bone resorption marker CTX and increased mRNA levels of 
Cathepsin K in bone. These findings are consistent with previous reports 
from the global life-long ARKO models demonstrating high bone 
turnover osteoporosis mainly caused by increased bone resorption(100,102). 
 
Androgens are considered key determinants of male cortical radial bone 
growth and, similar to humans, androgens promote the expansion of the 
periosteum in growing male rodents. One may speculate that AR 
expression during sexual maturation is crucial for the cortical radial 
expansion in male mice. However, in the present study similar effects on 
the cortical bone was observed by pre-pubertal and post-pubertal AR in-
activation, arguing against a specific role of the AR for cortical radial 
expansion during sexual maturation. A limitation with the present study 
was that we did not evaluate periosteal bone formation rate with the sen-
sitive dynamic histomorphometric technique and, therefore, we cannot 
exclude minor effects on cortical radial bone expansion. 
 
Longitudinal bone growth during sexual maturation in males is 
dependent on sex steroid actions(171). The finding in the present study that 
longitudinal bone growth was not significantly affected by pre-pubertal 
AR inactivation supports previous human and animal studies 
demonstrating that longitudinal bone growth during sexual maturation in 
males is mainly regulated by estrogen acting on ERα(77,172-174). 
 
In contrast to our finding that AR is required for the maintenance of both 
trabecular and cortical bone in adult male mice, pre-pubertal but not post-
pubertal AR expression was required for the development of a normal fat 
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mass. Mice with pre-pubertal inactivation of AR had increased fat mass 
associated with elevated serum leptin levels. It is well-known that 
androgen deficiency is associated with obesity, metabolic syndrome, and 
type 2 diabetes mellitus in men, but the mechanisms behind these 
associations remain unclear(175). Previous studies have demonstrated that 
male mice with global lifelong inactivation of AR developed late onset 
obesity(176). Our findings together with previous studies using mice with 
global lifelong AR inactivation, indicate that AR expression during 
puberty is crucial for normal fat mass homeostasis in adult mice.  
5.4 Role of post-translational modification of the 
AR in bone  
AR signaling can be regulated by different PTMs, including 
phosphorylation, acetylation, SUMOylation, ubiquitination and 
methylation(71). Most studies of the importance of PTMs are based on in 
vitro experiments, but recent in vivo studies have identified that PTMs of 
the AR are involved in the onset and progression of human diseases, 
including cancer. For instance, phosphorylation of the AR has been 
associated with hormone refractory prostate cancer and decreased 
disease-specific survival(177-179). Furthermore, AR acetylation has been 
shown to modulate AR activity and prostate cancer cell survival(180,181). 
The number of studies evaluating the effects of PTMs in different nuclear 
receptors for bone metabolism is limited, but we recently demonstrated 
that palmitoylation of ERα is required for a normal estrogenic response in 
bone(182,183). However, the role of PTMs in the AR for bone metabolism is 
unknown. 
 
In Paper IV, we demonstrate for the first time in vivo that SUMOylation 
of the AR regulates both cortical and trabecular bone mass. Mice devoid 
of the two SUMOylation sites (K381 and K500) displayed significantly 
reduced cortical bone thickness as well as trabecular bone mass in the 
long bones. The reduced trabecular bone mass was the result of reduced 
number of osteoblasts associated with reduced bone formation rate. 
These results suggest that SUMOylation of the AR increases AR 
transcriptional activity in the bone tissue. 
 
Although the exact mechanism of action of the SUMOylation of the AR 
is not clarified, it has been suggested that AR SUMOylation is important 
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for the recruitment of coactivators and co-repressors(184). Based on previ-
ous in vitro studies, the SUMOylation was initially suggested to repress 
the transcriptional activity of the receptor(74,75). However, recent genome-
wide gene expression analyses of prostate cancer cells stably expressing 
SUMOylation-deficient AR demonstrated that the SUMOylation of the 
AR modulated the AR function in a target gene and pathway selective 
manner(76). In that study, SUMOylation of the AR mainly regulated 
pathways linked to cellular movement, cell death, cellular proliferation, 
cellular development and cell cycle. Kaikkonen et al also suggested in 
vitro, that the degree of SUMOylation of the AR depends on the binding 
of a ligand to the receptor, and unliganded AR or antagonist-bound AR 
are only weakly SUMOylated compared with agonist-bound AR(75).  
 
Importantly, the male mice devoid of AR SUMOylation in Paper IV, 
were apparently healthy, displayed a normal longitudinal bone growth, 
had normal AR levels in bone and seminal vesicles and had no signs of 
disturbed feedback regulation of serum T. These findings demonstrate 
that the physiological role of AR SUMOylation in vivo is tissue-specific 
with a clear role for bone metabolism while some other major androgen-
dependent tissues are unaffected, supporting the previous in vitro study 
suggesting that the SUMOylation of the AR modulates the AR function 
in a cell- or tissue specific manner(76). We propose that therapies enhanc-
ing AR SUMOylation might result in bone-specific anabolic effects with 
minimal adverse effects in other tissues. 
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6. Conclusions  
Increased knowledge about the signaling mechanisms of androgens via 
the AR is needed for the development of new bone-specific SARMs with 
minimal systemic side effects. There is also a need for more knowledge 
about the skeletal effects of newly developed endocrine drugs used for 
treatment of prostate cancer. From the results presented in this thesis, we 
conclude that signaling mechanisms via the AR expressed by immature 
osteoblast-lineage cells are of importance for the androgenic effect on 
trabecular bone mass but not cortical bone mass. Furthermore, adult AR 
expression is required for the maintenance of both the trabecular and 
cortical bone in adult male mice. SUMOylation of the AR regulates bone 
mass but not the weights of androgen-responsive reproductive tissues, 
suggesting that therapies targeting AR SUMOylation might result in 
bone-specific anabolic effects with minimal adverse effects in other 
tissues. Finally, the recently developed antiandrogenic drug 
enzalutamide, used in clinical practice for treatment of prostate cancer 
patients, reduces the bone mass in the axial but not in the appendicular 
skeleton. The findings in this thesis may contribute to important 
knowledge for the development of new specific treatment options for 
men with osteoporosis and safer endocrine treatments with minimal 
skeletal side effects for men with prostate cancer. 	  
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7. Future perspective  
In order to develop bone-specific SARMs with minimal adverse effects 
in other tissues, more knowledge about the signaling mechanisms of 
androgens via the AR is needed. In contrast to the variety of SERMs that 
have been developed to date for different purposes, few SARMs have 
advanced beyond phase II proof-of-concept and there is not yet any 
SARM approved by the FDA or EMA.  
Results from this thesis demonstrate that AR expression in osteoblast-
lineage cells is of no importance for the cortical bone of male mice. This 
is rather unexpected since androgens are known to regulate cortical bone 
mass. Furthermore, previous studies have shown that AR expression in 
osteoclasts is also not crucial for cortical bone mass(152,154). These data 
demonstrate that the primary target cells for the AR action on cortical 
bone must be outside the bone. It has been suggested that the effects of 
AR on the cortical bone may be indirect via effects on cells within the 
bone marrow, muscle cells or nerve cells(94,155,156). We believe that further 
studies investigating the primary target cells of importance for AR ac-
tions in cortical bone are clearly warranted.                                                                  
Furthermore, targeting AR actions in a tissue-specific manner with 
minimal systemic adverse effects has been challenging. Importantly, in 
this thesis we demonstrate for the first time in vivo that manipulations of 
SUMOylation of the AR result in tissue-specific AR-mediated effects. 
Inactivation of AR SUMOylation reduced both cortical and trabecular 
bone mass whereas the weights of other androgen-sensitive organs such 
as seminal vesicles and the muscle levator ani were unaffected. New 
therapies enhancing AR SUMOylation might therefore result in bone-
specific anabolic effects with minimal adverse effects in reproductive 
tissues. In this thesis, we did not study the exact mechanisms for the tis-
sue-specific in vivo effects of AR SUMOylation. It has been suggested 
that SUMOylation of AR is important for the recruitment of different co-
activators and co-repressors and it is likely that this regulation is 
dependent on the cell context. Further studies examining the cellular 
mechanisms behind the tissue-specific effects of AR SUMOylation are 
clearly warranted. 
Enzalutamide is the first and only FDA-approved oral medication for 
both non-metastatic and metastatic castration-resistant prostate cancer. 
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Furthermore, a recent clinical Phase 2 study of enzalutamide monothera-
py in hormone-naïve prostate cancer revealed that this treatment substan-
tially reduced PSA levels, suggesting that enzalutamide monotherapy 
might, in the future, be considered as an early treatment for men with 
hormone-naïve prostate cancer. As we demonstrate in the present thesis 
that enzalutamide treatment reduces bone mass in the axial skeleton, we 
propose that the possible long term skeletal side effects of enzalutamide, 
especially when used as monotherapy, should be evaluated in a well-
powered clinical study. However, based on the results in the present 
study, we anticipate that the skeletal side effects with enzalutamide mon-
otherapy, affecting only androgenic signaling, will be less pronounced 
compared with the skeletal side effects of ADT, affecting both androgen-
ic and estrogenic signaling pathways in the skeleton.  
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